VanEck Pharmaceutical ETF (PPH)
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
The State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and higher assets under management than the VanEck Pharmaceutical ETF VanEck Pharmaceutical ETF focuses exclusively on pharmaceuticals while State Street Health Care Select Sector SPDR ETF covers medical equipment and healthcare services Historical data shows VanEck Pharmaceutical ETF has delivered higher 5-year growth but also experienced a deeper maximum drawdown
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?
The VanEck Pharmaceutical ETF provides a lower expense ratio and a more substantial dividend yield than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF delivered higher 1-year total returns but has lagged the VanEck fund over a 5-year horizon.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem
VanEck Pharmaceutical ETF offers a concentrated portfolio focused exclusively on drug manufacturers. iShares Global Healthcare ETF provides broader diversification across more than 100 companies in the global medical sector.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline.
Avalon Trust Co Has $24.89 Million Position in VanEck Pharmaceutical ETF $PPH
Avalon Trust Co lessened its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 1.8% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 275,400 shares of the company's stock after selling 5,077 shares during the quarter. VanEck Pharmaceutical ETF makes
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
VanEck Pharmaceutical ETF $PPH Shares Sold by Adamsbrown Wealth Consultants LLC
Adamsbrown Wealth Consultants LLC lowered its position in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 30.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,899 shares of the company's stock after selling 59,077 shares during the quarter. VanEck Pharmaceutical
VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund's concentrated bet on GLP-1 manufacturers makes this a call option on the market's continued growth. Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) combined represented nearly one-third of the ETF. If you believe the... VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion.
Why PPH Keeps Working When Single Themes Break
The VanEck Pharmaceutical ETF offers concentrated exposure to large-cap global pharma leaders, balancing growth, defensive, and non-drug cash flow stabilizers. PPH has demonstrated resilience, outperforming during market drawdowns and delivering an ~11.2% CAGR over five years with lower volatility than the S&P 500. The ETF's structure avoids excessive mega-cap or early-stage risk, with performance driven by earnings, product cycles, and disciplined capital allocation.
Fisher Asset Management LLC Sells 1,263,699 Shares of VanEck Pharmaceutical ETF $PPH
Fisher Asset Management LLC reduced its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 98.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,001 shares of the company's stock after selling 1,263,699 shares during the period.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
Top Pharmaceutical Companies Shaping the Future of Healthcare
Pharma's strong pipelines, reduced policy risks, and demand growth drive renewed investor interest. PPH offers targeted access to top innovators like Eli Lilly and Merck.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
PPH: Excellent Pharmaceutical ETF, But Bad Timing To Invest
VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings and lack of recent momentum suggest stockpicking may be preferable currently. Despite a competitive expense ratio and attractive dividend yield, PPH's defensive portfolio misses out on high-growth opportunities in emerging markets and AI.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.